Brought to you by 
Tolero gets exclusive global rights to Sanofi's alvocidib
29 May 2020
Executive Summary
Tolero Pharmaceuticals Inc. (developing drugs that target cellular pathways for cancer and related diseases) has licensed exclusive worldwide rights to develop and commercialize Sanofi’s CDK inhibitor alvocidib (also known as flavopiridol) for multiple cancers.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Tolero gets exclusive global rights to Sanofi's alvocidib
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice